AC
AVIR icon

Aldebaran Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Aldebaran Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$410K Sell
88,180
-1,766
-2% -$8.78K 0.31% 33
2026
Q1 		$484K Sell
89,946
-583
-0.6% -$2.68K 0.37% 32
2025
Q4 		$323K Buy
+90,529
New +$288K 0.29% 32
2025
Q2 		– Sell
-37,500
Closed -$112K – 36
2025
Q1 		$112K Buy
+37,500
New +$117K 0.11% 40

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aldebaran Capital's AVIR Position: Q2 2026 in Review

Aldebaran Capital reduced its Atea Pharmaceuticals (AVIR) stake by 2% in Q2 2026, selling an estimated $8.78K and leaving 88,180 shares worth $410K. The position accounts for 0.31% of the portfolio, ranked #33.

Aldebaran Capital first reported a position in AVIR in Q1 2025 and has held it in 4 quarters since. The position peaked at $484K in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Aldebaran Capital held 88,180 shares of Atea Pharmaceuticals worth $410K as of Q2 2026.
  • Aldebaran Capital sold 1,766 Atea Pharmaceuticals shares in Q2 2026, an estimated $8.78K.
  • Atea Pharmaceuticals made up 0.31% of Aldebaran Capital's portfolio in Q2 2026, its #33 holding.
  • Aldebaran Capital first reported a position in Atea Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • Aldebaran Capital's Atea Pharmaceuticals position peaked at $484K in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Aldebaran Capital's 13F filing for Q2 2026, filed 14 Aug 2026.